Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

Investors are expected to be cautious with NATCOPHARM, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 8.045083
debtToEquity 2.912000
earningsGrowth -0.375000
revenueGrowth -0.374000
grossMargins 0.856240
operatingMargins -0.017270
trailingEps 104.150000
forwardEps 41.270000

NATCOPHARM's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
NATCO Pharma Limited's negative gross and operating margins indicate that the company is unable to generate profit from its core business activities. This suggests financial strain and could be a sign of deeper cost management issues.
NATCOPHARM's forward EPS being less than trailing EPS suggests the company may see a drop in profitability this year. This signals potential financial challenges and a less optimistic outlook for earnings growth.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


In recent market activity, 20 sales of NATCOPHARM shares took place, with market price at 1344.6024963378907.NATCOPHARM had 1 buy transactions, with market price of 821.5999755859375.The trend of more buys compared to sells around NATCO Pharma Limited's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


Analysts have shown a buy bias for NATCO Pharma Limited, marking it as a favorable investment option. This could inspire investors to see NATCO Pharma Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.